Active	Status	Sponsor type	Region	Phase	Filter
13 Active 9 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Casale, Thomas
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis	Recruiting	3	450	Europe, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Perennial Allergic Rhinitis (PAR)	10/25	02/27
NCT05363670: Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma	Completed	2	18	US	ARS-1, Albuterol MDI, Placebo	ARS Pharmaceuticals, Inc.	Asthma	02/24	02/24
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria	Recruiting	2	154	Europe, Canada, US	Oral EP262, Placebo	Escient Pharmaceuticals, Inc	Chronic Spontaneous Urticaria	06/25	07/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	Recruiting	1/2	192	Canada, US	Peanut SLIT-tablet, Placebo	ALK-Abelló A/S, Parexel	Peanut Allergy	01/26	02/26
Smith, Catherine
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	Recruiting	1/2	192	Canada, US	Peanut SLIT-tablet, Placebo	ALK-Abelló A/S, Parexel	Peanut Allergy	01/26	02/26
ZN-d5-004C, NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Jul 2024 - Dec 2024 : Preliminary data r/r/ AML	Terminated	1/2	40	US	ZN-d5 ZN-c3, Study Drug, ZN-c3	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.	Acute Myeloid Leukemia (AML)	07/24	07/24